By NEIL UNMACK
The Swiss giant is putting three drugs in development into a new entity backed by investors. With biotech markets hot, there’s room for copycat deals.
Published: July 30, 2015 at 12:00AM
from NYT Business Day http://ift.tt/1LRLjqW
from WordPress http://ift.tt/1ShxSWB
via Hadi Aboukhater
No comments:
Post a Comment